3期临床-话题@MedSci

#3期临床#

90篇内容 | 2809人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1911234, encodeId=d7ec191123441, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=罗氏和基因泰克启动3期临床试验：评价双特异性抗体faricimab在湿性老年性黄斑变性中的潜力, objectType=article, longId=162129, objectId=56b216212948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56b216212948, replyNumber=0, likeNumber=75, createdTime=2019-12-06, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56b216212948, moduleTitle=罗氏和基因泰克启动3期临床试验：评价双特异性抗体faricimab在湿性老年性黄斑变性中的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56b216212948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911245, encodeId=d93219112459e, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=武田登革热疫苗在大规模的3期临床试验中有效率达80％, objectType=article, longId=182563, objectId=72bc182563be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72bc182563be, replyNumber=0, likeNumber=82, createdTime=2019-11-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72bc182563be, moduleTitle=武田登革热疫苗在大规模的3期临床试验中有效率达80％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72bc182563be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911232, encodeId=007e1911232fc, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Santhera的Syros在Duchenne型肌营养不良症3期临床研究中大获成功, objectType=article, longId=161123, objectId=fa8c1611239e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa8c1611239e, replyNumber=0, likeNumber=78, createdTime=2019-12-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa8c1611239e, moduleTitle=Santhera的Syros在Duchenne型肌营养不良症3期临床研究中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa8c1611239e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911243, encodeId=9919191124357, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=降胆固醇RNAi疗法再获佳绩，达到两项3期临床试验终点, objectType=article, longId=180087, objectId=c1d718008e7f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1d718008e7f, replyNumber=0, likeNumber=0, createdTime=2020-08-31, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1d718008e7f, moduleTitle=降胆固醇RNAi疗法再获佳绩，达到两项3期临床试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1d718008e7f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911241, encodeId=9c5219112418d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=口服索马鲁肽3期临床表现不凡，未来谁主导糖尿病治疗格局？, objectType=article, longId=168554, objectId=0a7d1685544a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a7d1685544a, replyNumber=0, likeNumber=109, createdTime=2020-01-31, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a7d1685544a, moduleTitle=口服索马鲁肽3期临床表现不凡，未来谁主导糖尿病治疗格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a7d1685544a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911237, encodeId=418f191123ea8, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？, objectType=article, longId=165870, objectId=a56a1658e0d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56a1658e0d1, replyNumber=0, likeNumber=73, createdTime=2020-04-13, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56a1658e0d1, moduleTitle=O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56a1658e0d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911235, encodeId=176b1911235dc, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, objectType=article, longId=162132, objectId=47be16213263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47be16213263, replyNumber=0, likeNumber=78, createdTime=2019-07-12, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47be16213263, moduleTitle=3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47be16213263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911238, encodeId=c9911911238c3, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究, objectType=article, longId=166113, objectId=36251661133d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36251661133d, replyNumber=0, likeNumber=65, createdTime=2019-06-16, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36251661133d, moduleTitle=GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36251661133d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911231, encodeId=ec95191123161, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=Aurinia完成了免疫抑制剂Voclosporin治疗狼疮性肾炎的3期临床试验的患者招募, objectType=article, longId=149702, objectId=9828149e02e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9828149e02e2, replyNumber=0, likeNumber=72, createdTime=2018-12-23, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9828149e02e2, moduleTitle=Aurinia完成了免疫抑制剂Voclosporin治疗狼疮性肾炎的3期临床试验的患者招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9828149e02e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911233, encodeId=da4419112331f, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, objectType=article, longId=161939, objectId=7e591619392f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e591619392f, replyNumber=0, likeNumber=66, createdTime=2019-12-17, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e591619392f, moduleTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e591619392f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911227, encodeId=a0bc191122ed3, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=重磅！阿斯利康药物奥拉帕尼在卵巢癌3期临床试验中显著延长生存期, objectType=article, longId=92752, objectId=b15992e526b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b15992e526b, replyNumber=0, likeNumber=58, createdTime=2017-10-06, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b15992e526b, moduleTitle=重磅！阿斯利康药物奥拉帕尼在卵巢癌3期临床试验中显著延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b15992e526b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911226, encodeId=9bec191122680, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=卵巢癌新药olaparib获3期临床突破, objectType=article, longId=92108, objectId=5ff2921087a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff2921087a, replyNumber=0, likeNumber=67, createdTime=2017-08-08, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff2921087a, moduleTitle=卵巢癌新药olaparib获3期临床突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff2921087a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911224, encodeId=d13219112244d, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=优于化疗！阿斯利康乳腺癌新药3期临床结果良好, objectType=article, longId=89342, objectId=762889342e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=762889342e9, replyNumber=0, likeNumber=71, createdTime=2017-06-10, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=762889342e9, moduleTitle=优于化疗！阿斯利康乳腺癌新药3期临床结果良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=762889342e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911225, encodeId=c2d7191122585, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=重磅！ViiV&nbspHealthcare&nbspHIV新型药物组合3期临床试验获得成功, objectType=article, longId=90598, objectId=dd06905989e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd06905989e, replyNumber=0, likeNumber=52, createdTime=2017-11-02, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd06905989e, moduleTitle=重磅！ViiV&nbspHealthcare&nbspHIV新型药物组合3期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd06905989e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911230, encodeId=f055191123030, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=突破性RNAi疗法早期数据显著，即将开展3期临床, objectType=article, longId=103681, objectId=7eda1036815a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7eda1036815a, replyNumber=0, likeNumber=85, createdTime=2017-10-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7eda1036815a, moduleTitle=突破性RNAi疗法早期数据显著，即将开展3期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7eda1036815a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911228, encodeId=3253191122887, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=意外之获！诺华心衰药物Entresto在3期临床试验中可改善血糖控制, objectType=article, longId=96279, objectId=06a2962e9cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06a2962e9cc, replyNumber=0, likeNumber=0, createdTime=2017-04-22, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06a2962e9cc, moduleTitle=意外之获！诺华心衰药物Entresto在3期临床试验中可改善血糖控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06a2962e9cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911229, encodeId=88d7191122944, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=膀胱癌药物3期临床达主要终点, objectType=article, longId=100370, objectId=138c1003e005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=138c1003e005, replyNumber=0, likeNumber=120, createdTime=2017-07-06, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=138c1003e005, moduleTitle=膀胱癌药物3期临床达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=138c1003e005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911221, encodeId=3b8719112216c, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=艾滋病新复方药3期临床试验达主要终点, objectType=article, longId=85189, objectId=47ed85189ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47ed85189ef, replyNumber=0, likeNumber=69, createdTime=2017-12-02, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47ed85189ef, moduleTitle=艾滋病新复方药3期临床试验达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47ed85189ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911218, encodeId=0432191121810, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=乳腺癌新药3期临床疗效显著，已向FDA提交新药申请, objectType=article, longId=73682, objectId=6f29e36828d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f29e36828d, replyNumber=0, likeNumber=0, createdTime=2017-05-28, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f29e36828d, moduleTitle=乳腺癌新药3期临床疗效显著，已向FDA提交新药申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f29e36828d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1911217, encodeId=417c191121ec7, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, objectTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, objectType=article, longId=73238, objectId=b19de323897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19de323897, replyNumber=0, likeNumber=72, createdTime=2016-08-19, rootId=0, userName=andy2087, userId=d275294, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19de323897, moduleTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19de323897)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

3期临床

2020-05-29

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

罗氏和基因泰克启动3期临床试验：评价双特异性抗体faricimab在湿性老年性黄斑变性中的潜力

2019-12-06

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

武田登革热疫苗在大规模的3期临床试验中有效率达80％

2019-11-19

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Santhera的Syros在Duchenne型肌营养不良症3期临床研究中大获成功

2019-12-19

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

降胆固醇RNAi疗法再获佳绩，达到两项3期临床试验终点

2020-08-31

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

口服索马鲁肽3期临床表现不凡，未来谁主导糖尿病治疗格局？

2020-01-31

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

O药一线治疗胶质母细胞瘤3期临床失败销量不及K药成定局？

2020-04-13

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

3期临床试验证实，武田的整合素单抗Entyvio治疗溃疡性结肠炎优于抗肿瘤坏死因子单抗修美乐

2019-07-12

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

GENFIT宣布DSMB的积极建议，将继续进行Elafibranor治疗非酒精性脂肪性肝炎的3期临床研究

2019-06-16

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

Aurinia完成了免疫抑制剂Voclosporin治疗狼疮性肾炎的3期临床试验的患者招募

2018-12-23

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒

2019-12-17

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

重磅！阿斯利康药物奥拉帕尼在卵巢癌3期临床试验中显著延长生存期

2017-10-06

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

卵巢癌新药olaparib获3期临床突破

2017-08-08

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

优于化疗！阿斯利康乳腺癌新药3期临床结果良好

2017-06-10

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

重磅！ViiV&nbspHealthcare&nbspHIV新型药物组合3期临床试验获得成功

2017-11-02

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

突破性RNAi疗法早期数据显著，即将开展3期临床

2017-10-19

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

意外之获！诺华心衰药物Entresto在3期临床试验中可改善血糖控制

2017-04-22

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

膀胱癌药物3期临床达主要终点

2017-07-06

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

艾滋病新复方药3期临床试验达主要终点

2017-12-02

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

乳腺癌新药3期临床疗效显著，已向FDA提交新药申请

2017-05-28

andy2087 (审核中...)

前往app查看评论内容

#3期临床#

第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功

2016-08-19

科室
- - 订阅+
  - 更多科室
工具
服务